Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

red around a class of small peptide molecules called lantibiotics, a drug class that, until now, has been underexploited due to the lack of adequate research tools. Novacta's lantibiotic platform has given rise to a number of potential drug candidates, including those in the C. difficile programme. Other programmes include one targeting methicillin-resistant Staphylococcus aureus (MRSA) infection and others targeting Gram-negative infections. For further information, please visit our website at www.novactabio.com.

About Lantibiotics

Lantibiotics are a naturally occurring class of antibiotic peptide compounds found in a large number of bacteria. They take their name from the lanthionine amino acids found within their structure ( lanthionine-containing antibiotics). Lantibiotics have demonstrated potential to treat infections caused by agents such as C. difficile and MRSA. Conventional medicinal chemistry has been unable to manipulate the structure of the naturally occurring compounds into the optimised forms that have the potential to treat human disease. However, Novacta's proprietary technologies allow the structural manipulation and optimisation of activity which is necessary to unlock the potential of this novel and under-exploited class of compounds.

    Please contact with enquiries:

    Celtic Pharma Holdings Advisors
    John Mayo / Stephen Parker
    LLP
    Tel: +44(20)7291-5456
    stephen.parker@celticpharmaholdings.com

    Novacta Biosystems Ltd.
    Georg Buchner
    VP, Corporate & Business Development
    Tel: +44(0)1707-356130
    georg.buchner@novactabio.com

    Citigate Dewe Rogerson Limited
    David Dible / Chris Gardner
    Tel: +44(0)20-7638-9571
    david.dible@
'/>"/>

SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/15/2014)... Israel , Dec. 15, 2014 /PRNewswire/ ... a leading developer of adult stem cell technologies for ... Therapeutics Ltd. was awarded a grant of approximately $1.1 ... the Chief Scientist (OCS).  This is the eighth year ... from the Office of the Chief Scientist, which is ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Penn State will receive $5 million over four ... a National Center for Nanotechnology Applications and Career ... national leader in nanotechnology education and workforce development ... was home to the NSF Regional Center for ...
... (Nasdaq: KERX ) announced today that it ... stating that Nasdaq Marketplace Rule,4310(c)(4), which requires companies ... share, has been temporarily suspended. Based on this ... until January 23, 2009, to,achieve compliance with Rule ...
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) announced ... I,Study to Evaluate Systemic Wild-Type Reovirus (REOLYSIN(R)) ... Malignancies" will be available in,the November/December issue ... of the International Society for Biological Therapy ...
Cached Biology Technology:Penn State gets $5M NSF grant for Nanotech Applications and Career Knowledge 2Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting 3
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... (Turkey), 12󈝼 September 2009 Mental disorders are a global ... care systems. In the world, there are some 500 million ... mental disorders range as one of the leading causes of ... prevalence of mental and neurological disorders is expected to grow ...
... pulled back to warmer climates when the International Polar Year wrapped ... to the poles for a more focused investigation into the effects ... is David Hik, a University of Alberta biology professor and a ... of the state of the planet,s polar regions," said Hik. "But ...
... is progressing faster than in any other location on Earth. ... new studies indicating that the changes are astonishingly fast. Many ... warming causes species from southern areas to migrate north, where ... The renowned Science magazine will publish a ...
Cached Biology News:Fighting the burden of mental disorders 2The change in Arctic nature foreshadows the global environment of the future 2
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... innovation from Magnetofection technology, SilenceMag is ... available. Simple, rapid and easy to ... non toxic. Specifically designed for siRNA ... at very low doses of siRNA.,SilenceMag ...
... C 4 H 10 O 2 ... PRODUCT SPECIFICATIONS Form: White crystalline powder ... 97% Identity: By IR Melting Point: ... Oxidized DTT: less than or equal ...
... Feature Extraction Software reads ... files to prepare microarray data ... , * one 2-year ... for NFP/Academic accounts , * ...
Biology Products: